ConocoPhillips
Energy
ConocoPhillips (COP) Stock News
The latest COP headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
ConocoPhillips (COP) Outpaces Stock Market Gains: What You Should Know
ConocoPhillips (COP) rose 1.53% to $127.06 in the latest session, outperforming the S&P 500's 0.2% gain. However, the stock has declined 8.78% over the past month. The company is expected to report Q3 earnings on November 5, 2026, with projected EPS of $2.58 (up 60.25% YoY) and revenue of $17.3 billion (up 11.47% YoY). COP currently holds a Zacks Rank #3 (Hold) with a Forward P/E of 11.87, trading at a discount to its industry average of 19.26.
- GlobeNewswire Inc.·
COPART (CPRT) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Copart, Inc. on Behalf of Copart Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Copart, Inc. following the announcement that CEO Jeff Liaw will step down effective July 31, 2026. The news triggered an 8.02% stock price decline ($2.45 per share) on June 29, 2026. The firm is seeking stockholders who suffered losses to discuss potential securities law violations and unlawful business practices.
- GlobeNewswire Inc.·
Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology
Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics have announced a definitive business combination agreement. Upon closing, the companies will form Ignite Proteomics Holdings, Inc. (PubCo), to be listed on the NYSE. The transaction values Ignite at a $150 million pro forma enterprise value and is expected to close in the second half of 2026. Ignite Proteomics specializes in pathway-level protein analytics for precision oncology.